Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1

Özkaya Sahin, Gülsen LU ; Holmgren, Birgitta G LU ; da Silva, Zacarias ; Nielsen, Jens ; Nowroozalizadeh, Salma ; Esbjörnsson, Joakim LU orcid ; Månsson, Fredrik LU ; Andersson, Sören ; Norrgren, Hans LU and Aaby, Peter , et al. (2012) In Journal of Virology 86(2). p.961-971
Abstract
HIV-2 has a lower pathogenicity and transmission rate than HIV-1. Neutralizing antibodies could be contributing to these observations. Here we explored side by side potency and breadth of intratype and intertype neutralizing activity (NAc) in plasma of 20 HIV-1, 20 HIV-2 and 11 dually HIV-1/2 (HIV-D) seropositive individuals from Guinea-Bissau, West Africa. Panels of primary isolates, five HIV-1 and five HIV-2, were tested in a plaque reduction assay using U87.CD4-CCR5 cells as targets. Intratype NAc in HIV-2 plasma was found to be considerably more potent, and also broader, than intratype NAc in HIV-1 plasma. This indicates that HIV-2 infected individuals display potent type-specific neutralizing antibodies, whereas such a strong... (More)
HIV-2 has a lower pathogenicity and transmission rate than HIV-1. Neutralizing antibodies could be contributing to these observations. Here we explored side by side potency and breadth of intratype and intertype neutralizing activity (NAc) in plasma of 20 HIV-1, 20 HIV-2 and 11 dually HIV-1/2 (HIV-D) seropositive individuals from Guinea-Bissau, West Africa. Panels of primary isolates, five HIV-1 and five HIV-2, were tested in a plaque reduction assay using U87.CD4-CCR5 cells as targets. Intratype NAc in HIV-2 plasma was found to be considerably more potent, and also broader, than intratype NAc in HIV-1 plasma. This indicates that HIV-2 infected individuals display potent type-specific neutralizing antibodies, whereas such a strong type-specific antibodies are absent in HIV-1 infection. Furthermore, potency of intratype NAc was positively associated with viral load of HIV-1, but not HIV-2, suggesting that NAc in HIV-1 infection is more antigen stimulation-dependent than in HIV-2 infection where plasma viral loads typically are at least tenfold lower than in HIV-1 infection. Intertype NAc of both HIV-1 and HIV-2 infected was instead of low potency. HIV-D subjects had NAc to HIV-2 with similar high potency as singly HIV-2 infected individuals, whereas neutralization of HIV-1 remained poor, indicating that the difference in NAc between HIV-1 and HIV-2 infections depends on the virus itself. We suggest that immunogenicity and/or antigenicity, meaning the neutralization phenotype, of HIV-2 is distinct from HIV-1, and that HIV-2 may display structures that favour triggering of potent neutralizing antibody responses. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Virology
volume
86
issue
2
pages
961 - 971
publisher
American Society for Microbiology
external identifiers
  • wos:000298674600028
  • pmid:22072782
  • scopus:84856890445
  • pmid:22072782
ISSN
1098-5514
DOI
10.1128/JVI.06315-11
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular Virology (013212007), Infectious Diseases Research Unit (013242010), Division of Infection Medicine (SUS) (013008000), Division of Medical Microbiology (013250400)
id
60b105d6-e183-4dd3-8c64-28a7f415f446 (old id 2220954)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22072782?dopt=Abstract
date added to LUP
2016-04-01 14:50:06
date last changed
2022-01-28 02:42:28
@article{60b105d6-e183-4dd3-8c64-28a7f415f446,
  abstract     = {{HIV-2 has a lower pathogenicity and transmission rate than HIV-1. Neutralizing antibodies could be contributing to these observations. Here we explored side by side potency and breadth of intratype and intertype neutralizing activity (NAc) in plasma of 20 HIV-1, 20 HIV-2 and 11 dually HIV-1/2 (HIV-D) seropositive individuals from Guinea-Bissau, West Africa. Panels of primary isolates, five HIV-1 and five HIV-2, were tested in a plaque reduction assay using U87.CD4-CCR5 cells as targets. Intratype NAc in HIV-2 plasma was found to be considerably more potent, and also broader, than intratype NAc in HIV-1 plasma. This indicates that HIV-2 infected individuals display potent type-specific neutralizing antibodies, whereas such a strong type-specific antibodies are absent in HIV-1 infection. Furthermore, potency of intratype NAc was positively associated with viral load of HIV-1, but not HIV-2, suggesting that NAc in HIV-1 infection is more antigen stimulation-dependent than in HIV-2 infection where plasma viral loads typically are at least tenfold lower than in HIV-1 infection. Intertype NAc of both HIV-1 and HIV-2 infected was instead of low potency. HIV-D subjects had NAc to HIV-2 with similar high potency as singly HIV-2 infected individuals, whereas neutralization of HIV-1 remained poor, indicating that the difference in NAc between HIV-1 and HIV-2 infections depends on the virus itself. We suggest that immunogenicity and/or antigenicity, meaning the neutralization phenotype, of HIV-2 is distinct from HIV-1, and that HIV-2 may display structures that favour triggering of potent neutralizing antibody responses.}},
  author       = {{Özkaya Sahin, Gülsen and Holmgren, Birgitta G and da Silva, Zacarias and Nielsen, Jens and Nowroozalizadeh, Salma and Esbjörnsson, Joakim and Månsson, Fredrik and Andersson, Sören and Norrgren, Hans and Aaby, Peter and Jansson, Marianne and Fenyö, Eva Maria}},
  issn         = {{1098-5514}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{961--971}},
  publisher    = {{American Society for Microbiology}},
  series       = {{Journal of Virology}},
  title        = {{Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1}},
  url          = {{http://dx.doi.org/10.1128/JVI.06315-11}},
  doi          = {{10.1128/JVI.06315-11}},
  volume       = {{86}},
  year         = {{2012}},
}